Induction of apoptosis in activated T cell blasts by suppressive macrophages: A possible immunotherapeutic approach for treatment of autoimmune disease
Kr. Mcintosh et Db. Drachman, Induction of apoptosis in activated T cell blasts by suppressive macrophages: A possible immunotherapeutic approach for treatment of autoimmune disease, CELL IMMUN, 193(1), 1999, pp. 24-35
Large suppressive macrophages (LSM)were induced by restimulating spleen cel
ls from rats with experimental autoimmune myasthenia gravis (EAMG) in vitro
, with the autoantigen acetylcholine receptor (AChR) in the presence of cyc
losporine A. LSM, purified from these cultures, are extremely potent suppre
ssors of AChR-stimulated lymphoproliferative responses and antibody respons
es in vitro. In the present study, we have analyzed the factors that determ
ine susceptibility of primed lymph node cells (pLNC) to suppression by LSM
and examined the fate of these cells. We found three characteristics of pLN
C that influenced their susceptibility to suppression. First, pLNC were req
uired to be activated (by antigen in these experiments) in order for suppre
ssion to occur. Resting lymphocytes were not affected, even when they were
present in cultures where antigen-activated lymphoblasts were being activel
y suppressed. Second, antigen specificity of the responder cells influenced
their susceptibility to suppression by LSM. AChR-specific cells were relat
ively more susceptible to suppression by AChR-induced LSM than pLNC primed
to an unrelated antigen, keyhole limpet hemocyanin. Third, T cell prolifera
tion was suppressed by LSM to a far greater extent than antibody production
by B cells. Using enriched T cell blasts generated from AChR-stimulated T
cell lines, we found that LSM rapidly suppressed [H-3]TdR uptake and induce
d DNA fragmentation assessed by the TUNEL assay (within 8 h of coculture) a
nd induced morphological signs of apoptosis of T cells (within 24 h). Few,
if any, blasts remained by 48 h of coculture. The ability to suppress an ac
tivated immune response permanently, without affecting nonactivated, bystan
der lymphocytes, holds promise that LSM, or their cellular products, could
be used for immunotherapy of autoimmune diseases such as myasthenia gravis.
(C) 1999 Academic Press.